FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 賽晶科技集團有限公司（於開曼群島註冊成立之有限公司） 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00580 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | 本月底法定/ ...

Group 1 - The core viewpoint of the article is that Sai Jing Technology expects significant revenue growth in 2025, driven by increased income from flexible transmission business and self-produced insulated gate bipolar transistors [2][3] - The company anticipates a revenue of approximately RMB 2.25 billion for the fiscal year 2025, representing a year-on-year increase of about 40% [2] - The expected profit attributable to the company's shareholders is projected to increase by approximately 30% during the same period [2] Group 2 - Revenue growth is primarily attributed to the delivery and revenue recognition of engineering orders, including projects in Saudi Arabia, Gansu-Zhejiang, and distributed flow controllers in Peru/Chile [2] - The company has expanded its market share through increased efforts in market development for its self-produced insulated gate bipolar transistors [2]

Core Viewpoint - Sijian Technology (00580) has seen a significant stock price increase, with a rise of over 7%, currently trading at HKD 2.15, with a transaction volume of HKD 21.85 million. The company announced a projected revenue of approximately RMB 2.25 billion for the fiscal year 2025, representing a year-on-year increase of about 40% [1]. Group 1 - The expected profit attributable to the company's shareholders is projected to increase by approximately 30% year-on-year [1]. - Revenue growth is primarily driven by increased income from the flexible transmission business, attributed to the delivery and revenue recognition of engineering orders [1]. - Key projects contributing to revenue include the Saudi Central-Southern ±500 kV flexible DC transmission converter station project, the Gansu-Zhejiang ±800 kV UHV DC transmission project, and the distributed power flow controller project in Peru/Chile [1]. Group 2 - There is also an increase in revenue from self-produced Insulated Gate Bipolar Transistors (IGBTs), due to the company's intensified market expansion efforts, leading to a gradual increase in market share [1].

Core Viewpoint - Sijian Technology (00580) has seen its stock price increase by over 11%, currently trading at HKD 2.11, with a transaction volume of HKD 11.25 million, following the announcement of significant revenue growth projections for the fiscal year ending December 31, 2025 [1] Financial Performance - The company expects revenue of approximately RMB 2.25 billion for the fiscal year ending December 31, 2025, representing an increase of about 40% compared to the fiscal year ending December 31, 2024 [1] - The anticipated increase in revenue is primarily driven by growth in the flexible transmission business, attributed to the delivery and revenue recognition of engineering orders, including projects in Saudi Arabia, Gansu-Zhejiang, and Peru/Chile [1] - The company also projects a 30% increase in profit attributable to equity holders for the fiscal year, mainly due to the rise in revenue leading to higher gross profit [1] Revenue Sources - Revenue growth is supported by increased income from self-produced Insulated Gate Bipolar Transistors (IGBTs), as the company expands its market presence and gradually increases its market share [1] - Additional income and gains are expected from foreign exchange gains and profits from foreign exchange forward contracts aimed at mitigating currency risk associated with foreign currency purchases [1]

Major Events - Longi Technology (09611) plans to globally offer 52.2591 million H-shares from January 14 to January 19 [1] - CK Life Sciences (00013) announced the results of the SACHI III study published in The Lancet [1] - Dongyang Sunshine Pharmaceutical (06887) launched an AI-driven R&D platform targeting the PROTAC mechanism, continuing to deepen its AI strategic layout [1] - Dongyao Pharmaceutical-B (01875) received a cash offer from WuXi AppTec (02268) at a premium of approximately 99%, with resumption of trading on January 15 [1] - Valiant Pharmaceuticals-B (09887) received Fast Track designation from the US FDA for its bispecific antibody, Opalizumab (LBL-024) [1] - Xunqi (03317) entered into a strategic cooperation framework agreement with Jinyong Investment to support digital transformation in investment research, trading, and risk management [1] Operating Performance - CITIC Securities (06030) reported a net profit attributable to shareholders of 30.051 billion yuan for 2025, an increase of 38.46% year-on-year [1] - CITIC Bank (00998) reported a net profit attributable to shareholders of 70.618 billion yuan for 2025, a year-on-year increase of 2.98% [1] - China General Nuclear Power New Energy (01811) completed a cumulative power generation of 19,000 GWh in 2025, a decrease of 0.8% year-on-year [1] - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 106.21 billion yuan for 2025 [1] - WuXi AppTec (02268) issued a profit warning, expecting a net profit growth of over 38% year-on-year for 2025 [1] - Jinyu Group (02009) issued a profit warning, anticipating a net loss attributable to shareholders of 900 million to 1.2 billion yuan for 2025 [1] - Saijing Technology (00580) issued a profit alert, expecting a net profit increase of approximately 30.0% for 2025 [1] - Beijing Beichen Industrial Co., Ltd. (00588) issued a profit warning, expecting a net loss attributable to shareholders of 2.696 billion to 3.38 billion yuan for 2025 [1]

Company News - CITIC Securities (06030.HK) reported a revenue of RMB 74.83 billion for the fiscal year 2025, representing a year-on-year increase of 28.75%, and a net profit of RMB 30.05 billion, up 38.46% year-on-year [2] - CITIC Bank (00998.HK) announced a total revenue of RMB 212.48 billion for 2025, a slight decrease of 0.55% year-on-year, while net profit increased by 2.98% to RMB 70.62 billion [2] - Beijing North Star Industrial (00588.HK) expects to continue reporting losses for the fiscal year ending December 31, 2025 [3] - Yuexiu Property (00123.HK) reported a cumulative contract sales amount of approximately RMB 106.21 billion for 2025, a decline of about 7.3% year-on-year, achieving 88.1% of its sales target [3] - Jiao Ge Peng You Holdings (01450.HK) achieved a total GMV of approximately RMB 6.49 billion in Q4 2025, a year-on-year increase of about 4.34%, with a cumulative GMV of RMB 16.02 billion for the year, up 6.23% [3] - Sai Jing Technology (00580.HK) anticipates a revenue of approximately RMB 2.25 billion for 2025, reflecting a year-on-year increase of about 40% due to increased revenue from flexible transmission business [3] - China General Nuclear Power New Energy (01811.HK) reported a cumulative power generation of 19,000 GWh for 2025, a decrease of 0.8% year-on-year, with variations in different energy sources [3] - Morning News Technology (02000.HK) reported an unaudited revenue of HKD 397 million for 2025, a decrease of 7.4% year-on-year [3] Financing and Buyback Activities - Chow Tai Fook Enterprises (00659.HK) applied for the registration of debt financing instruments totaling no more than RMB 5 billion [7] - Tencent Holdings (00700.HK) repurchased 1.006 million shares at a cost of approximately HKD 636 million, with repurchase prices ranging from HKD 626 to HKD 638 [7] - Xiaomi Group-W (01810.HK) repurchased 4 million shares for approximately HKD 151 million, with repurchase prices between HKD 37.61 and HKD 42.50 [7] Research and Development - Hutchison China MediTech (00013.HK) announced the publication of SACHI III study results in The Lancet [4] - Laka Pharmaceuticals-B (02105.HK) had its clinical trial application for the new drug LAE118 accepted by the U.S. FDA [5] Other News - Yuanxu Technology (08637.HK) announced a short suspension of trading starting January 14, pending the release of insider information [6] - Haidilao (06862.HK) redeemed USD 600 million of its 2.150% notes due in 2026 [2]

Core Viewpoint - The company, Sai Jing Technology (00580), anticipates a revenue of approximately RMB 2.25 billion for the fiscal year ending December 31, 2025, representing a 40% increase compared to the fiscal year ending December 31, 2024, primarily driven by growth in the flexible transmission business and increased market share in self-produced insulated gate bipolar transistors [1] Revenue Growth - The expected revenue increase is attributed to the delivery and revenue recognition of engineering orders, including projects such as the ±500 kV flexible DC transmission converter station in Central and Southern Saudi Arabia, the ±800 kV UHVDC transmission project from Gansu to Zhejiang, and the distributed power flow controller project in Peru/Chile [1] - The company is also experiencing revenue growth from self-produced insulated gate bipolar transistors due to enhanced market expansion efforts, leading to a gradual increase in market share [1] Profit Increase - The company forecasts a 30% increase in profit attributable to equity holders of the parent company for the reporting year, mainly due to the increase in revenue leading to higher gross profit [1] - Additional income and gains are expected, including foreign exchange gains and profits from foreign exchange forward contracts signed to mitigate foreign currency procurement risks [1]

Core Viewpoint - Sai Jing Technology (00580.HK) has announced a positive earnings forecast, expecting a revenue of approximately RMB 2.25 billion for the fiscal year 2025, representing a 40% increase compared to 2024, driven by growth in flexible transmission business and increased market share in self-produced insulated gate bipolar transistors [1] Group 1: Revenue Growth - The expected revenue increase is attributed to the delivery and revenue recognition of engineering orders in the flexible transmission sector, including projects in Saudi Arabia, Gansu-Zhejiang, and Peru/Chile [1] - The company anticipates a significant rise in revenue from self-produced insulated gate bipolar transistors due to enhanced market expansion efforts [1] Group 2: Profit Increase - The company forecasts a 30% increase in profit attributable to the owners of the parent company for 2025 compared to 2024, primarily driven by increased revenue leading to higher gross profit [1] - Additional income and gains are expected to rise, particularly from foreign exchange gains and profits from foreign exchange forward contracts aimed at mitigating currency risk in foreign currency purchases [1]

及预计本集团于报告年度内取得的母公司拥有人应占溢利较截至2024年12月31日止年度增加约30.0%， 主要由于收入增加导致毛利增加;及其他收入及收益增加，主要包括汇兑收益及为降低以外币进行采购 的汇兑风险而签订的外汇远期合约收益。 赛晶科技(00580)发布公告，预计本集团于截至2025年12月31日报告年度内的收入约人民币22.5亿元，较 截至2024年12月31日止年度增加约40.0%，主要由于来自柔性输电业务领域的收入增加，得益于有关工 程订单产品陆续交付及收入确认，即沙特中部-南部±500千伏柔性直流输电换流站工程、甘肃-浙江±800 千伏特高压直流输电工程及秘鲁╱智利分佈式潮流控制器工程;及自产绝缘栅双极型晶体管的收入增 加，得益于本集团加大市场拓展力度而令市场份额逐步扩大。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告的全部或任何部份內容而產生或因倚賴該等 內容而引致的任何損失承擔任何責任。 正面盈利預告 本公告乃由賽晶科技集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合交易所 有限公司證券上市規則（「上市規則」）13.09(2)(a)條及香港法例第571章證券及期貨條例第XIVA部之內 幕消息條文（定義見上市規則）之規定而作出。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東及潛在投資者，董事會根據本集團截至二零 二五年十二月三十一日止年度（「報告年度」）之未經審核綜合管理賬目對以下財務數據作出的初步評 估： 1 1. 預計本集團於報告年度內的收入約人民幣22.5億元，較截至二零二四年十二月三十一日止年度增 加約40.0%，主要由於(a)來自柔性輸電業務領域的收入增加，得益於有關工程訂單產品陸續交付 及收入確認，即沙特中部－南部±500千伏柔性直流輸電換流站工程、甘肅－浙江±800千伏特 高壓直流輸電工程及秘魯╱智利分佈式潮流控制器工程；及(b)自產絕緣柵雙 ...